444891-19-4

Basic information

• Product Name: Benzeneacetonitrile, .alpha.-broMo-2-chloro-
• Synonyms: Benzeneacetonitrile, .alpha.-broMo-2-chloro-;2-Bromo-2-(2-chlorophenyl)acetonitrile
• CAS NO: 444891-19-4
• Molecular Formula: C₈H₅BrClN
• Molecular Weight: 230.489
• Mol File: 444891-19-4.mol

Chemical Properties

• Boiling Point: 260.4±25.0 °C(Predicted)
• Appearance: /
• Density: 1.628±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Benzeneacetonitrile, .alpha.-broMo-2-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetonitrile, .alpha.-broMo-2-chloro-(444891-19-4)
• EPA Substance Registry System: Benzeneacetonitrile, .alpha.-broMo-2-chloro-(444891-19-4)

Safety Data

• Hazardous Substances Data: 444891-19-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Benzeneacetonitrile, alpha-bromo-2-chloro-, is used as a reagent in the synthesis of various organic compounds, particularly in the pharmaceutical industry. Its unique chemical properties allow for the creation of a wide range of pharmaceutical drugs and agrochemicals.
Used in Fine Chemical Industry:
In the fine chemical industry, Benzeneacetonitrile, alpha-bromo-2-chloro-, is also utilized as a reagent for the synthesis of complex organic compounds. Its versatility in chemical reactions makes it an essential component in the production of specialty chemicals.
Safety Precautions:
Due to its reactivity and potential hazards, Benzeneacetonitrile, alpha-bromo-2-chloro-, should be handled with care and proper safety measures. It is crucial to follow all safety guidelines and protocols when working with this chemical compound to ensure the safety of individuals and the environment.

Upstream product

• 2856-63-5 2-Chlorophenylacetonitrile 

Downstream Products

• 444728-11-4 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)acetonitrile 
• 144457-28-3 SR 26334 
• 120202-66-6 (S)-(+)-clopidogrel bisulfate 
• 90055-68-8 (+/-)-methyl-(2-chlorophenyl)-(4,5,6,7-4H-thieno[3,2,-c]pyrid-5-yl) acetamide 
• 90055-55-3 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)acetic acid 
• 1147350-77-3 cis-5-thiol metabolite 
• 113665-84-2 (S)-(+)-clopidogrel 
• 90055-48-4 clopidogrel 

Relevant articles and documents

Prodrugs of anti-platelet agents

The invention relates to the compounds of formula I, formula II, formula Ia, formula IIb or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula Ia, formula IIb and methods for treating or preventing atherothrombosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment or management of ischemia, stroke, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovascular diseases and blood clots.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROTHROMBOSIS

The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral administration- transdermal administration, transmucosal, syrups, topical, extended release, sustained release, or injection. Such compositions may foe used to treatment of vascular disorders or conditions such as thrombotic cerebrovascular or cardiovascular disease or its associated complications.

PRODRUGS OF ANTI-PLATELET AGENTS

Disclosed is the compounds of formula (I), formula (II), formula (la), formula (IIb) or its pharmaceutical acceptable salts, polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising and effective amount of formula (I), formula (II), formula (la), formula (lIb) and may be used to treatment or management of ischemia, stroke, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovasculard diseases and blood colts.

COMPOSITIONS AND METHODS FOR TREATING ATHEROTHROMBOSIS

Provided are compounds of formula (I), pharmaceutical acceptable salts, polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising the compounds may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup or injection, and may be used for the treatment or management of ischemia, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovascular diseases and blood clots.

PREPARATION OF CLOPIDOGREL AND ITS ANALOGUES METHYL TETRAHYDROTHIENOPYRIDINE ACETATE COMPOUNDS

The present invention disclosed a preparation method of Clopidogrel (X=2-Cl) and its analogues of methyl tetrahydrothienopyridine acetate (I) by using halogen phenyl acetonitrile (VIII) as starting material and tetrahydrothienopyridine acetonitrile (IV), tetrahydrothienopyridine acetate (V) as key intermediates, and further using kinetic resolution to prepare the optical active Clopidogrel and compounds of methyl tetrahydrothenopridine acetate of formula (XII). The Clopidogrel of present invention is a novel high effective and safety drug for inhibition of platelet aggregation. This invention applied systematic technique of racemization of unwanted optical active enantiomer, recover recycle and reuse of resolution agent etc., with greater economic advantages and suitable for commercial scale industrial production. Wherein: X represents atoms of hydrogen, fluorine, chlorine, bromine or iodine, M represents an alkali metal ion.

Preparation of Clopidogrel and Its Analogues Methyl Tetrahydrothienopyridine Acetate Compuunds

The present invention disclosed a preparation method of Clopidogrel (X=2-Cl) and its analogues of methyl tetrahydrothienopyridine acetate (I) by using halogen phenyl acetonitrile (VIII) as starting material and tetrahydrothienopyridine acetonitrile (IV), tetrahydrothienopyridine acetate (V) as key intermediates, and further using kinetic resolution to prepare the optical active Clopidogrel and compounds of methyl tetrahydrothenopridine acetate of formula (XII). The Clopidogrel of present invention is a novel high effective and safety drug for inhibition of platelet aggregation. This invention applied systematic technique of racemization of unwanted optical active enantiomer, recover recycle and reuse of resolution agent etc., with greater economic advantages and suitable for commercial scale industrial production. Wherein: X represents atoms of hydrogen, fluorine, chlorine, bromine or iodine, M represents an alkali metal ion.

Synthetic improvements in the preparation of clopidogrel

Synthetic improvements in the preparation of clopidogrel are described. The synthesis was accomplished in four steps or one-pot in above 70% overall yield. The process featured PTC catalyzed alkaline hydrolysis of the key intermediate 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetonitrile and highly effective kinetic resolution of racemic clopidogrel using L-camphorsulphonic acid in toluene and has been successfully used in a 50-kg pilot test.